Abstract 6171
Background
Clinical trials using immune checkpoint inhibitors (ICPIs) against immune inhibitory receptor ligand 1 (PD-L1) have failed to show clinical benefit for glioblastoma (GBM) patients. This is likely due to multiple factors, including but not limited to, the immunologically cold GBM microenvironment lacking effector immune cells. PD-L1 expression in tumour cells can be regulated by epidermal growth factor receptor/janus kinase 2 (EGFR/JAK2) signalling that might weaken the antitumor immune response by increasing PD-L1 level. Furthermore, EGFR is mutationally activated in approximately 50% of GBMs. Therefore, we analysed changes in EGFR and PD-L1 expression levels in the intraoperative specimens obtained from patients diagnosed with primary GBMs.
Methods
In total, 27 patients with newly diagnosed GBM underwent surgery and were investigated for mRNA and protein expression level either of Ki67, EGFR/EGFRvIII and PD-L1 by quantitative reverse transcription-PCR (qRT-PCR) or immunohistochemistry (IHC).
Results
EGFR overexpression (IHC H-score > 200 [0-300]) was detected in 8/27(30%) specimens as assessed by IHC, whereas 25/27 samples (93%) showed increased EGFR mRNA expression, suggesting a higher sensitivity of qRT-PCR analysis. Of the 25, 10 patients were harbouring EGFRvIII mutation. PD-L1 protein expression (2+ and 3+ staining in > 5% cells) was present in 16/27(60%) samples, of which concurrent elevation of PD-L1 and EGFR mRNA copy numbers was seen in 9/16 samples. In contrast, IHC revealed EGFR overexpression in only 2/16 PDL-1 positive patients. Ki67 staining revealed great variety in proliferation status of the GBMs, with a median Ki67 index of 30 (range 10-62).
Conclusions
Collectively, these results confirm that primary GBMs are characterised by a considerable heterogeneity of EGFR, EGFRvIII and PD-L1 expressions at both mRNA and protein levels. The PD-L1 mRNA expression was found to be associated with EGFR mRNA copy number only in small group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NCNOPUS13#2017/25/B/NZ5/00039, KNW-1-108/N/8/O.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract